March 18, 2004
The Assembly's health committee chair, Richard Gottfried (D-Manhattan), and Jeffrion Aubry (D-Queens), chair of the Assembly's corrections committee, remained critical of the prison's policy of treating HCV-infected inmates only if they are incarcerated for the year needed to complete the drug regimen. Consequently, just a few hundred of the estimated 9,200 inmates who show signs of HCV infection are treated while incarcerated.
According to Wright, released inmates do not have particularly good histories of follow-up with doctors and sticking to health care routines. Prison officials have also had difficulty in lining up HCV-treatment programs outside of prisons for inmates released unexpectedly, prior to treatment conclusion. "Treatment ends up with large gaps in it, which is not good health care," said Wright. Discontinuing the treatment schedule could make later attempts to treat HCV impossible, added Wright.
Gottfried said treatment for inmates is often delayed because they cannot become immediately eligible for Medicaid upon their release, and he urged for a plan allowing the paperwork for Medicaid to be started well in advance of the end of inmates' sentences. Dr. Guthrie Birkhead, director of New York's AIDS Institute, said social service officials are hesitant to accept Medicaid applications for people who do not apply in person and who are not currently living in the local district.
03.15.04; Joel Stashenko
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|No Evidence of Accelerated Brain Aging in HIV-Positive People on Effective ART|
|Final HIV Research Highlights From CROI 2017|
|With Possibilities for Long-Acting HIV Treatment, Modern Science Creates Modern ART|
|Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study|
|No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study|
|Really Rapid Review -- CROI 2017, Seattle|